March 22, 2021, the State Food and Drug Administration announced that Hainan Green Island Pharmaceutical Co., LTD. Terazosin hydrochloride tablets were approved successfully! The "one-stop" clinical study of this variety was completed by Duzheng Biology (the cooperative co-construction unit Hunan Institute of Occupational Disease Prevention and Control was responsible for the clinical, the smart recruitment, the first lead medicine was responsible for THE SMO service, weights and data management and statistical analysis).
Terazosin hydrochloride tablet is a 289 - base drug catalog variety. The diastolic blood pressure reduction agent is used for the treatment of mild to moderate hypertension and can be used in combination with thiazide diuretics or other antihypertensive medications, or alone when other medications are not appropriate or ineffective. Oral administration of the drug may also be appropriate for the treatment of symptoms caused by benign prostatic hyperplasia (BPH).
As a "one-stop" service platform for clinical research, Duzheng Biological has helped many pharmaceutical companies successfully obtain approval. After July 22, the company carried out more than 200 BE/PK studies, among which pantoprazole sodium enteric-coated tablets were approved first and second in China. The first donepezil hydrochloride tablet approved in China; Solina succinate new national third approved; Escitalopram oxalate was first approved in Hunan. Outstanding clinical research achievements in innovative drugs, the company has completed more than 10 early clinical research projects, projects covering a number of professional fields. At present, several projects are under development.
In the future, the company will continue to adhere to the concept of "innovation and truth-seeking", take the customer as the center, and provide high-quality and professional pharmaceutical and medical device clinical research "one-stop" service for global biomedical enterprises.